VIDEO: B-cell maturation antigen evolving in multiple myeloma

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

We're excited in the multiple myeloma that we continue to work in developing newer and or different treatment regimens that help our patients and this include BCMA award. So B-cell maturation antigen is an evolving field where we have three ways of targeting this receptor, including the antibody direct conjugate, as well as the chimeric antigen receptor T-cell therapy, or CAR T-cell therapy, and also bispecific antibodies. So some of the pipeline that we're looking for is agents that are used without a step up priming dose, for example, and in case of bispecific, they're all more community friendly.

They are given without the need of hospitalization and or are given in less frequent fashion to help patients being able to be on those drugs. We also have developments on how we target or do CAR T-cell therapy. So there are development in using GBRC5D target for CAR T-cell therapy and the studies are under development and this hopefully can present another way of targeting CAR T-cell therapy in the field of multiple myeloma. We're also trying to improve the drugs that we already have for a long period of time, including the immunomodulatory drugs. There are a newer agent of drug called CELMoD that may work, you know, better and achieving better, you know, responses and or less side effects, but this needs to be confirmed in more of randomized control studies to make sure that those is rather the fact and that's helpful for patients.